Mitoxantrone-related acute leukemia in MS: An open or closed book?

Neurology

Volumn 80, Issue 16, 2013, Pages 1529-1533

  Chan, Andrew ^a   Lo Coco, Francesco ^b  

^a ST JOSEF HOSPITAL   (Germany)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTHRAQUINONE; ARSENIC TRIOXIDE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIPODOPHYLLOTOXIN; ETOPOSIDE; MITOXANTRONE; RETINOIC ACID; ALKYLATING AGENT;

ACUTE LEUKEMIA; CANCER RISK; CARDIOTOXICITY; CLINICAL PRACTICE; DNA REPAIR; GENETIC RISK; HEMATOLOGIC DISEASE; HUMAN; LEUKOPENIA; META ANALYSIS; MULTIPLE SCLEROSIS; NEUROLOGIST; PATHOGENESIS; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; REVIEW; RISK FACTOR; THROMBOCYTOPENIA; CHEMICALLY INDUCED DISORDER; GENETICS; LEUKEMIA; NEUROLOGIC EXAMINATION; PHYSIOLOGIC MONITORING; RISK;

ANTINEOPLASTIC AGENTS, ALKYLATING; HUMANS; LEUKEMIA; MITOXANTRONE; MONITORING, PHYSIOLOGIC; MULTIPLE SCLEROSIS; NEUROLOGIC EXAMINATION; RISK; RISK FACTORS;

MLCS; MLOWN;

EID: 84878769943     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e31828cf891     Document Type: Review

References (37)

1. Edan G, Miller D, Clanet M, et al. Therapeutic effect of mitoxantrone combined with methylprednisolone in multiple sclerosis: a randomised multicentre study of active disease using MRI and clinical criteria. J Neurol Neurosurg Psychiatry 1997;62:112-118.
2. Hartung HP, Gonsette R, Konig N, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet 2002;360:2018-2025.
3. Millefìorini E, Gasperini C, Pozzilli C, et al. Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome. J Neurol 1997;244:153-159.
4. Van De Wyngaert FA, Beguin C, D'Hooghe MB, et al. A double-blind clinical trial of mitoxantrone versus methylprednisolone in relapsing, secondary progressive multiple sclerosis. Acta Neurol Belg 2001;101:210-216.
5. Chan A, Weilbach FX, Toyka KV, Gold R. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol 2005;139:152-158.
6. Neuhaus O, Wiendl H, Kieseier BC, et al. Multiple sclerosis: mitoxantrone promotes differential effects on immunocompetent cells in vitro. J Neuroimmunol 2005;168:128-137.
7. Kopadze T, Dehmel T, Hartung HP, Stuve O. Kieseier BC. Inhibition by mitoxantrone of in vitro migration of immunocompetent cells: a possible mechanism for therapeutic efficacy in the treatment of multiple sclerosis. Arch Neurol 2006;63:1572-1578.
8. Cocco E, Sardu C, Gallo P, et al. Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study. Mult Scler 2008;14:1225-1233.
9. Ghalie RG, Edan G, Laurent M, et al. Cardiac adverse effects associated with mitoxantrone (Novantrone) therapy in patients with MS. Neurology 2002;59:909-913.
10. Ghalie RG, Mauch E, Edan G, et al. A study of therapyrelated acute leukaemia after mitoxantrone therapy for multiple sclerosis. Mult Scler 2002;8:441-445.
11. Marriott JJ, Miyasaki JM, Gronseth G, O'Connor PW. Evidence Report: the efficacy and safety of mitoxantrone (Novantrone) in the treatment of multiple sclerosis: report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2010;74:1463-1470.
12. Pascual AM, Tellez N, Bosca I, et al. Revision of the risk of secondary leukaemia after mitoxantrone in multiple sclerosis populations is required. Mult Scler 2009;15:1303-1310.
13. Martinelli V, Cocco E, Capra R, et al. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2011;77:1887-1895.
14. Stroet A, Hemmelmann C, Starck M, et al. Incidence of therapy-related acute leukaemia in mitoxantrone-treated multiple sclerosis patients in Germany. Ther Adv Neurol Disord 2012;5:75-79.
15. Le Page E, Leray E, Edan G; French Mitoxantrone Safety Group. Long-term safety profile of mitoxantrone in a French cohort of 802 multiple sclerosis patients: a 5-year prospective study. Mult Scler 2011;17:867-875.
16. Stroet A, Gold R, Chan A. Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone. Neurology 2012;78:933-934.
17. Wundes A, Kraft GH, Bowen JD, Gooley TA, Nash RA. Mitoxantrone for worsening multiple sclerosis: tolerability, toxicity, adherence and efficacy in the clinical setting. Clin Neurol Neurosurg 2010;112:876-882.
18. Gonsette RE. Mitoxantrone in progressive multiple sclerosis: when and how to treat? J Neurol Sci 2003;206:203-208.
19. Edan G, Comi G, Le PE, Leray E, Rocca MA, Filippi M. Mitoxantrone prior to interferon beta-1b in aggressive relapsing multiple sclerosis: a 3-year randomised trial. J Neurol Neurosurg Psychiatry 2011;82:1344-1350.
20. Hasan SK, Buttari F, Ottone T, et al. Risk of acute promyelocytic leukemia in multiple sclerosis: coding variants of DNA repair genes. Neurology 2011;76:1059-1065.
21. Nitiss JL. Targeting DNA topoisomerase II in cancer chemotherapy. Nat Rev Cancer 2009;9:338-350.
22. Mistry AR, Felix CA, Whitmarsh RJ, et al. DNA topoisomerase II in therapy-related acute promyelocytic leukemia. N Engl J Med 2005;352:1529-1538.
23. Fortune JM, Osheroff N. Topoisomerase II as a target for anticancer drugs: when enzymes stop being nice. Prog Nucleic Acid Res Mol Biol 2000;64:221-253.
24. Hasan SK, Mays AN, Ottone T, et al. Molecular analysis of t (15;17) genomic breakpoints in secondary acute promyelocytic leukemia arising after treatment of multiple sclerosis. Blood 2008;112:3383-3390.
25. Mays AN, Osheroff N, Xiao Y, et al. Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t (15;17) therapy-related acute promyelocytic leukemia. Blood 2010;115:326-330.
26. De Campos-Nebel M, Larripa I, Gonzalez-Cid M. Topoisomerase II-mediated DNA damage is differently repaired during the cell cycle by non-homologous end joining and homologous recombination. PLoS One 2010;5.
27. Vollmer T, Stewart T, Baxter N. Mitoxantrone and cytotoxic drugs' mechanisms of action. Neurology 2010;74(suppl 1):S41-S46.
28. Rowley JD, Olney HJ. International workshop on the relationship of prior therapy to balanced chromosome aberrations in therapy-related myelodysplastic syndromes and acute leukemia: overview report. Genes Chromosomes Cancer 2002;33:331-345.
29. Pedersen-Bjergaard J, Andersen MK, Andersen MT, Christiansen DH. Genetics oftherapy-related myelodysplasia and acute myeloid leukemia. Leukemia 2008;22:240-248.
30. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989;58:351-375.
31. Chen GL, Yang L, Rowe TC, Halligan BD, Tewey KM, Liu LF. Nonintercalative antitumor drugs interfere with the breakage-reunion reaction of mammalian DNA topoisomerase II. J Biol Chem 1984;259:13560-13566.
32. Cotte S, Von AN, Kruse N, et al. ABC-transporter genepolymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis. Brain 2009;132:2517-2530.
33. Dorr J, Bitsch A, Schmailzl KJ, et al. Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment. Neurology 2009;73:991-993.
34. Ammatuna E, Montesinos P, Hasan SK, et al. Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis. Haematologica 2011;96:621-625.
35. Lo Coco F, Diverio D, Avvisati G, et al. Therapy of molecular relapse in acute promyelocytic leukemia. Blood 1999;94:2225-2229.
36. Esteve J, Escoda L, Martin G, et al. Outcome of patients with acute promyelocytic leukemia failing to front-line treatment with all-trans retinoic acid and anthracycline-based chemotherapy (PETHEMA protocols LPA96 and LPA99): benefit of an early intervention. Leukemia 2007;21:446-452.
37. Chan A, Pirmohamed M, Comabella M. Pharmacogenomics in neurology: current state and future steps. Ann Neurol 2011;70:684-697.